ArticleCell chemical biology2024

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.

Sasikumar Kotagiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.